Evidence map›Paper›PMID 29082776›Full record

ArticleAIDS care2018

HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis.

J Carlo Hojilla, Megha Mehrotra, Hong-Ha M Truong, David V Glidden, K Rivet Amico, Vanessa McMahan, David Vlahov, Suwat Chariyalertsak, Juan Vicente Guanira, Robert M Grant and 1 more

Abstract readMulticenter Study
In one paragraph

Article in AIDS care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

J Carlo Hojillaa School of Nursing , University of California , San Francisco , CA , USA.ORCID 0000-0001-8654-8445
Megha Mehrotrab Department of Epidemiology and Biostatistics , University of California , San Francisco , CA , USA.
Hong-Ha M Truongd Center for AIDS Prevention Studies , University of California , San Francisco , CA , USA.
David V Gliddenb Department of Epidemiology and Biostatistics , University of California , San Francisco , CA , USA.
K Rivet Amicoe School of Public Health , University of Michigan , Ann Arbor , MI , USA.
Vanessa McMahanc Gladstone Institute of Virology and Immunology , San Francisco , CA , USA.
David Vlahovf School of Nursing , Yale University , New Haven , CT.
Suwat Chariyalertsakg Research Institute for Health Sciences , Chang Mai , Thailand.
Juan Vicente Guanirah Investigaciones Medicas en Salud , Lima , Peru.
Robert M Grantc Gladstone Institute of Virology and Immunology , San Francisco , CA , USA.
For The iPrEx Study Teama School of Nursing , University of California , San Francisco , CA , USA.
University of California, San Francisco · USGladstone Institutes · USEsSALUD · PEUniversity of Michigan · USYale University · US

Funding

Chemoprophylaxis for HIV Prevention in Men SupplementU01AI064002 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2005 to 2011
$41.3M
Chemoprophylaxis and HIV Host InteractionsR01AI118575 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANT, ROBERT M. · 2015 to 2019
$2.9M
RCT of an integrative intervention for non-treatment-seeking meth usersR01DA033854 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CARRICO, ADAM WAYNE, MOSKOWITZ, JUDITH T. · 2013 to 2017
$2.8M
Clinical and Transtional Science InstituteTL1TR000144 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$643k
NCATS NIH HHS TL1 TR000144NIAID NIH HHS R01 AI118575NIAID NIH HHS U01 AI064002NIDA NIH HHS R01 DA033854
6 · The paper itself

Abstract

HIV pre-exposure prophyalxis (PrEP) might lead individuals to view serodisclosure as unnecessary. We examined the prevalence of non-disclosure and lack of knowledge of partner status in a global cohort of men who have sex with men (MSM) and transgender women (TW) enrolled in the iPrEx Open Label Extension (OLE). We calculated prevalence ratios by fitting a logistic model and estimating predicted probabilities using marginal standardization. Prevalence of non-disclosure and lack of knowledge of partner status were highest in Thailand (73% and 74%, respectively) and lowest in the USA (23% and 37%, respectively). In adjusted analyses, PrEP use was not significantly associated with non-disclosure or lack of knowledge of partner status (p-values>0.05). We found that relationship characteristics were significantly associated with both outcomes. Non-disclosure was higher among casual (adjusted prevalence ratio [aPR] 1.54, [95% confidence interval 1.24-1.84]) and transactional sex partners (aPR 2.03, [1.44-2.62]), and among partners whom participants have known only minutes or hours before their first sexual encounter (aPR 1.62, [1.33-1.92]). Similarly, participants were less likely to know the HIV status of casual partners (aPR 1.50, [1.30-1.71]), transactional sex partners (aPR 1.62, [1.30-1.95]), and those they have known for only days or weeks (aPR 1.13, [0.99-1.27]) or minutes or hours (aPR 1.27, [1.11-1.42]). Our findings underscore the role of dyadic factors in influencing serodisclosure. Comprehensive risk reduction counseling provided in conjunction with PrEP that address relationship characteristics are needed to help patients navigate discussions around HIV status.

Indexed as

Self DisclosureAdultAgedFemaleHIV InfectionsHomosexuality, MaleHumansInterpersonal RelationsMaleMiddle AgedPre-Exposure ProphylaxisSexual PartnersSouth AfricaSouth AmericaThailandTransgender PersonsHIV preventionHIV serodisclosuremen who have sex with menpre-exposure prophylaxisPrEPtransgender women

Identifiers

PMID29082776
PMCPMC6087469
OpenAlexW2765197545

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.